These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30967632)

  • 41. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.
    Li J; Kent DG; Godfrey AL; Manning H; Nangalia J; Aziz A; Chen E; Saeb-Parsy K; Fink J; Sneade R; Hamilton TL; Pask DC; Silber Y; Zhao X; Ghevaert C; Liu P; Green AR
    Blood; 2014 May; 123(20):3139-51. PubMed ID: 24692758
    [TBL] [Abstract][Full Text] [Related]  

  • 42. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P; Levine RL
    Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].
    Zhu JF; Liu Y; Liu P; Jia MF; Cheng J; Zhao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):916-20. PubMed ID: 21867614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
    Vainchenker W; Constantinescu SN
    Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
    Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
    Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.
    Chen E; Ahn JS; Massie CE; Clynes D; Godfrey AL; Li J; Park HJ; Nangalia J; Silber Y; Mullally A; Gibbons RJ; Green AR
    Proc Natl Acad Sci U S A; 2014 Oct; 111(42):15190-5. PubMed ID: 25288776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms.
    Fung TK; Cheung AM; Kwong YL; Liang R; Leung AY
    Leuk Res; 2010 Oct; 34(10):1390-4. PubMed ID: 20170959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
    Wang J; Ishii T; Zhang W; Sozer S; Dai Y; Mascarenhas J; Najfeld V; Zhao ZJ; Hoffman R; Wisch N; Xu M
    Leukemia; 2009 Sep; 23(9):1577-86. PubMed ID: 19387466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target.
    Murakami S; Barroca V; Perié L; Bravard A; Bernardino-Sgherri J; Tisserand A; Devanand C; Edmond V; Magniez A; Tenreira Bento S; Torres C; Pasquier F; Plo I; Vainchenker W; Villeval JL; Roméo PH; Lewandowski D
    Blood Cancer Discov; 2022 Jul; 3(4):285-297. PubMed ID: 35290450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
    Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
    J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
    [TBL] [Abstract][Full Text] [Related]  

  • 51. JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.
    Kanduła Z; Janowski M; Więckowska B; Paczkowska E; Lewandowski K
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4789-4803. PubMed ID: 36242602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.
    Tsuruta-Kishino T; Koya J; Kataoka K; Narukawa K; Sumitomo Y; Kobayashi H; Sato T; Kurokawa M
    Oncogene; 2017 Jun; 36(23):3300-3311. PubMed ID: 28068330
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34
    Chen Y; Zhao H; Luo J; Liao Y; Tan K; Hu G
    Oncol Lett; 2021 May; 21(5):351. PubMed ID: 33747208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
    Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
    Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
    Liu L; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice.
    Jin X; Zhao W; Kirabo A; Park SO; Ho WT; Sayeski PP; Zhao ZJ
    J Immunol; 2014 Jul; 193(2):477-84. PubMed ID: 24920845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
    Geron I; Abrahamsson AE; Barroga CF; Kavalerchik E; Gotlib J; Hood JD; Durocher J; Mak CC; Noronha G; Soll RM; Tefferi A; Kaushansky K; Jamieson CH
    Cancer Cell; 2008 Apr; 13(4):321-30. PubMed ID: 18394555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinguishing essential thrombocythemia
    Silver RT; Krichevsky S
    Haematologica; 2019 Nov; 104(11):2200-2205. PubMed ID: 30948488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.